Latest Headlines

Latest Headlines

Sorin snatches up a Florida manufacturer's cardiac-lead business for $20M

Sorin Group is paying $20 million for a Florida manufacturer's cardiac-lead business, as well as its plans for new MRI-compatible cardiac leads.

Galapagos ships out its CRO biz for $179M to focus on R&D

Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.

Charles River snaps up Galapagos' CRO biz for $179M

Charles River Laboratories is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.

Vectura bags respiratory biotech Activaero for $181M

U.K. drugmaker Vectura has signed a deal to absorb Germany's Activaero and its pipeline of airway treatments for €130 million ($181 million), betting the biotech's respiratory candidates can more than make up for the price tag.

Clinipace dives into Asia with Choice Pharma buyout

North Carolina's Clinipace is looking to scale up its global presence, buying out Hong Kong CRO Choice Pharma and planning to merge its operations into a transcontinental player.

The top 10 med tech M&A deals of 2013

Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...

Report: InterMune eyed for a multibillion-dollar buyout

Fresh off positive results for its late-stage lung drug, InterMune has attracted some M&A interest from a flock of pharmaceutical companies, according to  Reuters, sending the biotech's shares up roughly 12% on Friday.

Last year's M&A darling, Biomet files for an IPO

Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.

INC buys its way into the Middle East with MEK deal

INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.

Roche's M&A budget opens up as it pays off Genentech deal debt

Roche's debt from its 2009 buyout of Genentech is winding down--and less money to pay means more money to play with, outgoing chairman Franz Humer says.